S. Gulnik

发表

Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.

S. Gulnik, L. Suvorov, B. Liu, 1995, Biochemistry.

A rapid method for quantifying cytoplasmic versus nuclear localization in endogenous peripheral blood leukocytes by conventional flow cytometry

S. Gulnik, George C. Brittain, 2017, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Drug resistance mutations can affect dimer stability of HIV‐1 protease at neutral pH

S. Gulnik, B. Yu, J. Erickson, 1999, Protein science : a publication of the Protein Society.

Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design.

R E Cachau, T. Bhat, J. Collins, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Conformational switching in an aspartic proteinase

John W. Erickson, S. Gulnik, J. Erickson, 1998, Nature Structural Biology.

Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease

Dale J. Kempf, John W. Erickson, Eric T. Baldwin, 1994 .

Design of sensitive fluorogenic substrates for human cathepsin D

J. Collins, S. Gulnik, L. Suvorov, 1997, FEBS letters.

5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.

G. Zeikus, E. Lunney, S. Gulnik, 2000, Journal of medicinal chemistry.

Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.

R E Cachau, P. Collins, T. Bhat, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Analysis of intracellular trafficking and interactions of cytoplasmic HIV-1 Rev mutants in living cells.

S. Gulnik, J. Erickson, R. Stauber, 1998, Virology.

Automated leukocyte processing by microfluidic deterministic lateral displacement

J. Sturm, A. Skelley, R. Austin, 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

De novo design of nonpeptidic HIV-1 protease inhibitors: Incorporation of structural water.

John W. Erickson, Stanley K. Burt, S. Gulnik, 1994 .

Human liver cathepsin D. Purification, crystallization and preliminary X-ray diffraction analysis of a lysosomal enzyme.

S. Gulnik, J. Erickson, E. Baldwin, 1992, Journal of molecular biology.

A Novel Semiconductor-Based Flow Cytometer with Enhanced Light-Scatter Sensitivity for the Analysis of Biological Nanoparticles

S. Gulnik, George C. Brittain, Marc-André Langlois, 2019, Scientific Reports.

Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?

T. Bhat, C. Debouck, S. Gulnik, 1998, Biochemistry.

Human treg cells are characterized by low/negative CD6 expression

S. Gulnik, J. Tung, Carlos A. Garcia Santana, 2014, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Unsymmetric nonpeptidic HIV protease inhibitors containing anthranilamide as a P2' ligand.

T. Bhat, S. Gulnik, B. Yu, 1998, Bioorganic & medicinal chemistry letters.

Reply to: Misinterpretation of solid sphere equivalent refractive index measurements and smallest detectable diameters of extracellular vesicles by flow cytometry

S. Gulnik, George C. Brittain, Marc-André Langlois, 2021, Scientific reports.

A novel putative transcription factor protein MYT2 that preferentially binds supercoiled DNA and induces DNA synthesis in quiescent cells

W. Shao, S. Gulnik, J. Erickson, 2000, FEBS letters.

Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.

T. Bhat, S. Gulnik, B. Liu, 1995, Structure.

Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2' replacement for the symmetry-based HIV protease inhibitors.

S. Gulnik, B. Yu, J. Erickson, 1996, Bioorganic & medicinal chemistry.

Enamino-oxindole HIV protease inhibitors.

S. Gulnik, J. Erickson, H. Yokoe, 2012, Bioorganic & medicinal chemistry letters.

Structure‐based subsite specificity mapping of human cathepsin D using statine‐based inhibitors

J. Collins, S. Gulnik, J. Erickson, 1997, Protein science : a publication of the Protein Society.

A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site

Arun K. Ghosh, S. Gulnik, H. Mitsuya, 2002, Journal of Virology.

In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine

S. Gulnik, J. Erickson, M. Nomizu, 1993, Antimicrobial Agents and Chemotherapy.

The Dimer Interfaces of Protease and Extra-Protease Domains Influence the Activation of Protease and the Specificity of GagPol Cleavage

A. Kaplan, S. Gulnik, S. Pettit, 2003, Journal of Virology.

Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.

C. Boucher, S. Gulnik, J. Erickson, 1999, AIDS.

Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from P. Falciparum

Jack R. Collins, Pavel Majer, Raul E. Cachau, 1996 .

Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.

S. Gulnik, L. Suvorov, J. Erickson, 1997, Biochemistry.

Rational design and synthesis of conformationally constrained inhibitors of human cathepsin D

J. Collins, S. Gulnik, J. Erickson, 2002 .

Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum.

S. Gulnik, O. Asojo, J. Ellman, 2003, Journal of molecular biology.

Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370.

Djamel Medjahed, S. Gulnik, J. Erickson, 2002, Acta crystallographica. Section D, Biological crystallography.

HIV protease: enzyme function and drug resistance.

S. Gulnik, J. Erickson, D. Xie, 2000, Vitamins and hormones.

Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases.

T. Bhat, S. Gulnik, J. Erickson, 1998, Advances in experimental medicine and biology.

Real‐time measurements of dark substrate catalysis

S. Gulnik, L. Suvorov, J. Erickson, 2008, Protein science : a publication of the Protein Society.

Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition.

J S Mills, B. Dunn, S. Gulnik, 1997, Biochimica et biophysica acta.

Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies.

S. Gulnik, J. Erickson, J W Erickson, 1999, AIDS.

Structure of human cathepsin D: comparison of inhibitor binding and subdomain displacement with other aspartic proteases.

T. Bhat, S. Gulnik, J. Erickson, 1995, Advances in experimental medicine and biology.

Approaches to the design of HIV protease inhibitors with improved resistance profiles

S. Gulnik, M. Eissenstat, 2008, Current opinion in HIV and AIDS.

Structural study of the type II 3-dehydroquinate dehydratase from Actinobacillus pleuropneumoniae.

D. Maes, S. Gulnik, B. Yu, 2004, Acta crystallographica. Section D, Biological crystallography.

Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.

A Wlodawer, A. Wlodawer, I. Weber, 1998, Biochemistry.

Utility of (His)6 tag for purification and refolding of proplasmepsin-2 and mutants with altered activation properties.

S. Gulnik, J. Erickson, E. Gustchina, 2002, Protein expression and purification.

Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.

T. Bhat, S. Gulnik, J. Erickson, 1998, Journal of medicinal chemistry.

Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease.

D. Ho, M. Markowitz, S. Gulnik, 1996, AIDS research and human retroviruses.

Unsymmetric Nonpeptidic HIV Protease Inhibitors Containing Anthranilamide as a P2′ Ligand.

T. Bhat, S. Gulnik, J. Erickson, 1999 .

Structure-based design of achiral anthranilamides as P2/P2′ surrogates for symmetry-based HIV protease inhibitors: design, synthesis, X-ray structure, enzyme inhibition and antiviral activity

T. Bhat, S. Gulnik, J. Erickson, 1995 .

Symmetry-based HIV Protease inhibitors: rational design of 2-methylbenzamides as novel P2/P2′ ligands

T. Bhat, S. Gulnik, J. Erickson, 1995 .

Human stomach cathepsin E action on human immunoglobulins.

S. Gulnik, N. Tarasova, A. F. Kisseljov, 1991, Advances in experimental medicine and biology.

A new type of aspartic proteinase inhibitors with a symmetric structure.

S. Gulnik, N. Tarasova, E. S. Oksenoit, 1991, Advances in Experimental Medicine and Biology.

Molecular dynamics of HIV-1 protease in complex with a difluoroketone-containing inhibitor: implications for the catalytic mechanism.

S. Gulnik, J. Erickson, A. M. Silva, 1995, Advances in Experimental Medicine and Biology.

Approaches to the design of HIV protease inhibitors with improved resistance profiles

S. Gulnik, M. Eissenstat, 2008, Current opinion in HIV and AIDS.